Avita Medical, INC 10-Q quarterly reports

AVITA Medical's Q2 2026 report shows an 18% revenue increase driven by product sales, but persistent operating losses and a significant accumulated deficit raise going concern issues.

AVITA Medical's Q1 2026 filing details revenue growth, operational expense reduction, and a new $60 million credit facility, while acknowledging ongoing going concern doubts.

AVITA Medical reported a 19% reduction in net loss for Q3 2025, despite a 13% revenue decline, driven by cost savings and new product launches, while facing ongoing debt covenant challenges and a CEO transition.

AVITA Medical, Inc. reported a 21% increase in Q2 2025 revenue and a 36% reduction in net loss, but faces substantial doubt about its ability to continue as a going concern due to debt covenant non-compliance and liquidity challenges.

Avita Medical obtained a waiver for a trailing 12-month revenue covenant while reporting a 67% increase in total revenues for the first quarter of 2025.

Avita Medical saw a significant increase in revenue during the third quarter of 2024, but also experienced a widening net loss compared to the same period last year.

AVITA Medical's second quarter results show a significant revenue increase driven by deeper market penetration and new customer acquisitions for their RECELL technology.

AVITA Medical's first quarter 2024 results show a 5.3% increase in revenue, but also a significant rise in operating expenses leading to a larger net loss compared to the same period last year.